Foresight Global Investors Inc. Lowers Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Foresight Global Investors Inc. cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 12.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,413 shares of the medical research company’s stock after selling 762 shares during the quarter. IQVIA comprises approximately 0.7% of Foresight Global Investors Inc.’s portfolio, making the stock its 25th biggest position. Foresight Global Investors Inc.’s holdings in IQVIA were worth $1,252,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. Laurel Wealth Advisors LLC lifted its holdings in shares of IQVIA by 1.1% during the third quarter. Laurel Wealth Advisors LLC now owns 4,710 shares of the medical research company’s stock valued at $927,000 after purchasing an additional 50 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in shares of IQVIA by 18.1% during the 3rd quarter. Parkside Financial Bank & Trust now owns 346 shares of the medical research company’s stock valued at $68,000 after acquiring an additional 53 shares during the last quarter. Private Advisor Group LLC raised its holdings in shares of IQVIA by 1.2% during the third quarter. Private Advisor Group LLC now owns 4,818 shares of the medical research company’s stock valued at $948,000 after purchasing an additional 56 shares during the last quarter. B. Riley Wealth Advisors Inc. lifted its position in IQVIA by 1.6% during the third quarter. B. Riley Wealth Advisors Inc. now owns 3,568 shares of the medical research company’s stock valued at $702,000 after purchasing an additional 56 shares during the period. Finally, Greenleaf Trust boosted its holdings in IQVIA by 1.9% in the fourth quarter. Greenleaf Trust now owns 3,154 shares of the medical research company’s stock worth $730,000 after purchasing an additional 58 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

IQV traded up $1.32 on Thursday, hitting $229.20. 643,740 shares of the company’s stock traded hands, compared to its average volume of 961,353. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 2.02. The firm has a market cap of $41.76 billion, a price-to-earnings ratio of 31.31, a P/E/G ratio of 2.16 and a beta of 1.52. The company’s 50 day simple moving average is $242.48 and its 200-day simple moving average is $225.08.

IQVIA (NYSE:IQV) last released its earnings results on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.82 by $0.02. The firm had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. The company’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.54 earnings per share. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 10.12 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Guggenheim cut IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Evercore ISI cut their price target on IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a research note on Friday, May 3rd. SVB Leerink assumed coverage on shares of IQVIA in a report on Monday, February 26th. They issued an “outperform” rating and a $290.00 price objective on the stock. UBS Group upped their target price on shares of IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Finally, BTIG Research began coverage on shares of IQVIA in a research note on Tuesday, February 13th. They set a “buy” rating and a $285.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $257.57.

Insider Buying and Selling

In related news, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Kevin C. Knightly sold 8,607 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the sale, the insider now directly owns 5,251 shares of the company’s stock, valued at approximately $1,313,642.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ari Bousbib sold 31,678 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the transaction, the insider now directly owns 796,752 shares in the company, valued at approximately $199,610,278.56. The disclosure for this sale can be found here. Over the last three months, insiders have sold 41,285 shares of company stock worth $10,331,003. Corporate insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.